Please assess the completion status of the following clinical trial:

Trial Title: S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Patients must have unresectable advanced or metastatic histologically or cytologically confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ)~  * Patients must not have received treatment for metastatic or unresectable disease~ * Patients must not have brain metastases~* Patients must have measurable and/or non-measurable disease~* Patients who have had HER-2 expression testing prior to patient consent to this study must be HER-2 negative; if HER-2 expression has not been tested prior to patient consent to this study, a second specimen must be submitted for HER-2 expression; if the specimen is HER-2 positive (or if HER-2 could not be evaluated), the patient will not be randomized~* Patients must have completed any prior neoadjuvant and adjuvant therapy for resectable disease at least 180 days prior to registration~PATIENT CHARACTERISTICS:~* Zubrod performance status of 0-1~* Hemoglobin ≥ 9 g/dL~* Absolute neutrophil count (ANC) ≥ 1,500/mcL~* Platelets ≥ 100,000/mcL~* Total bilirubin ≤ 1.5 mg/dL regardless of whether patients have liver involvement secondary to tumor~* AST and ALT both ≤ 3 times institutional upper limit of normal (IULN) unless the liver is involved with tumor, in which case both AST and ALT must be ≤ 5 times IULN~* Serum creatinine \< 1.5 mg/dL within 28 days prior to registration AND/OR calculated creatinine clearance \> 60 mL/min~* Patients must not have motor or sensory neuropathy \> Grade 1 using CTCAE version 4.0~* Patients must not be pregnant or nursing; women and men of reproductive potential must have agreed to use an effective contraceptive method~* No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for five years~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* All palliative radiation therapy alone must be completed at least 14 days prior to registration~* Patient must have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of cancer while on this protocol treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).